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Xing-Peng Wang1, Li-Jun Zhang2* and Lun-Gen Lu1*Abstract
Background & aim: Due to known limitations of liver biopsy, reliable non-invasive serum biomarkers for chronic
liver diseases are needed. We performed serum peptidomics for such investigation in compensated chronic
hepatitis B (CHB) patients.
Methods: Liquid chromatography combined with tandem mass spectrometry (LC-MS/MS) was used to identify
differentially expressed peptides in sera from 40 CHB patients (20 with S0G0-S1G1 and 20 with S3G3-S4G4). Ion pair
quantification from differentially expressed peptides in a validation set of sera from 86 CHB patients was done with
multiple reaction monitoring (MRM).
Results: 21 differentially represented peptide peaks were found through LC-MS/MS. Ion pairs generated from
eleven of these peptides (m/z < 800) were quantified by MRM. Summed peak area ratios of 6 ion pairs from peptide
m/z 520.3 (176.1, 353.7, 459.8, 503.3, 351.3, 593.1), which was identified as dihydroxyacetone kinase (DAK) fragment,
decreased from mild to advanced stages of fibrosis or inflammation. Area Under Receiver Operating Characteristic
Curves (AUROCs) of five ion models discriminating fibrosis degrees were 0.871 ~ 0.915 (S2-4 versus S0-1) and
0.804 ~ 0.924 (S3-4 versus S0-2). AUROCs discriminating inflammation grades were 0.840 ~ 0.902 (G2-4 versus G0-1)
and 0.787 ~ 0.888 (G3-4 versus G0-2). The diagnostic power of these models provides improved sensitivity and
specificity for predicting disease progression as compared to aspartate aminotransferase to platelet ratio index
(APRI), FIB-4, Forn’s index and serum DAK protein.
Conclusions: The peptide fragment (m/z 520.3) of DAK is a promising biomarker to guide timing of antiviral
treatment and to avoid liver biopsy in compensated CHB patients.
Keywords: Peptidome, Dihydroxyacetone kinase, Chronic hepatitis B, Multiple reaction monitoring,
Liquid chromatography combined with tandem mass spectrometryIntroduction
In China, chronic hepatitis B virus (HBV) infection is
the most common cause of chronic liver disease. The
number of hepatitis B surface antigen (HBsAg) carriers
was estimated 9.09% of the population [1]. Accurate
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reproduction in any medium, provided the orfor the management of patients with chronic hepatitis B
(CHB). Histological diagnosis via liver biopsy has long
been the gold standard for assessing the degree of fibro-
sis and inflammation, but is an invasive procedure with
inherent risks and sampling variability [2]. Non-invasive
strategies based on blood tests, including clinical sero-
logical models [3-6], serological glycomics and proteo-
mics [7-9], were recently successful in predicting
advanced stages of fibrosis and inflammation in some
settings. However, none of these tests can completely
replace liver biopsy.This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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means for identifying novel biomarkers [10-15]. Cir-
culating peptide fragments generated in body fluids or
tissues can reflect biological events and provide crit-
ical information for clinical diagnosis [16,17]. Quanti-
tation of peptide biomarkers in complex biological
matrices, such as human serum, is a challenging task.
A promising alternative method to antibody mediated
approaches is mass spectrometry based multiple reac-
tion monitoring (MRM) that allows accurately quanti-
fying peptide.
Aim of this study was to find useful serum biomarkers
indicating liver disease progression based on peptido-
mics in CHB patients. Liquid chromatography combined
with tandem mass spectrometry (LC-MS/MS) was used
to separate and identify differentially represented pep-
tides in sera of CHB patients. Serum expression levels of
such peptides were then quantitated by MRM.Materials and methods
The study included three parts: (I) a discovery study; (II)
a validation study and (III) a diagnosis study.Patients
126 CHB patients that were HBsAg positive for at least
6 months were enrolled from Shanghai First People’s
Hospital between 2008 and 2010. Patients were ex-
cluded, when they were co-infected with HIV or HCV,
consumed >30 g alcohol per day, had received antiviral
treatment, or without availability of sufficient liver
biopsy tissue (a minimum length of 1.0 cm of the liver
biopsy and at least 6 portal tracts included were the
inclusion criteria). All CHB patients included in our
study were compensated and end-stage liver disease was
excluded. The study was approved by the Ethics Com-
mittee of Shanghai First People’s Hospital and informed
consent was obtained from each patient. All patients
received percutaneous liver biopsy. Fibrotic stage and
inflammational grade of tissue samples were classified
according to the Scheuer classification [18,19].Serum peptide extraction
Peripheral blood was taken before breakfast, collected in
tubes containing EDTA-anticoagulant, and stored at -80°C
until use. Serum peptides were extracted as described
[20,21]; briefly, proteins were precipitated from serum by
rapid addition of two volumes acetonitrile containing 0.1%
trifluoroacetic acid, and immediately mixed by vortexing.
Samples were incubated at 4°C for 30 min and centrifuged
at 12,000 rpm for 30 min twice. The supernatant was
collected and dried by vacuum centrifugation (Labconco
Corporation, Kansas City, USA).Peptide profiling or identification by ion trap mass
spectrometry
Peptide samples were re-lysed in 50 μl 2% acetonitrile
(ACN), 0.1% formic acid (FA) and centrifuged. 15 μl of
the solution were separated by use of Ultimate 3,000
instruments (LC Packings, Dionex, USA) through a C-18
reversed-phase nanocolumn (75 μm id × 15 cm length,
3 μm, PepMapTM) with a linear gradient from 4% to 48%
acetonitrile and 0.1% formic acid for 60 minutes, after a
desalting step across a C-18 precolumn (300 μm id ×
5 mm, 5 μm, PepMapTM). Peptides eluted from the
reversed-phase nanocolumn were on line injected by
a PicoTip emitter nanospray needle (New Objective,
Woburn) for real-time ionization and peptide fragmenta-
tion on an Esquire HCT ion-trap mass spectrometer
(Bruker-Daltonics, Bremen, Germany). MS acquisition
parameters were set as follows: ESI-Ion-trap MS, positive
mode, time range: 600–4,500 seconds, scanning range:
m/z of 100–2,800, target mass: 900 m/z. Each sample was
analyzed three times, two for peptide profiling and one for
peptide identification. For peptide profiling, only MS
scanning was performed. For differentially represented
peptide identification, autoMS(n) was performed. Before
the experiment, HCT mass spectrometry was calibrated
by tune mix.
For peptide profiling, MS scan data were further analyzed
with ProfileAnalysis software (Bruker Daltonics, Germany)
for MS-T-Test Model analysis. Bucketing parameters were
as follows: Δ m/z =1 Da, Δ RT = 60 seconds. Each data set
was normalized to the sum of bucked values. Criteria of
differentially expressed peaks were p value < 0.05, with
m/z >300, retention time >10 minutes, fold change >1.5
and detection in more than 80% of samples. MS/MS data
were analyzed through calculation of scored peak intensity
(SPI). The peptide peak, which had a charge of +2 with
a score threshold of at least 10, or a charge of +1 or +3
with a score threshold of at least 13, was considered a
good hit, if it also had a SPI of at least 70. Furthermore,
all identified peptides will be checked to have p values
less than 0.05 (p < 0.05) [22].
To identify differentially represented peptides, autoMS(n)
data were processed with DataAnalysis software
(Bruker Daltonics, Germany) to generate a Mascot
generic format file (MGF, Matrix Science Inc.). The
MGF file was used to search against the IPI_human
database by Mascot. Peptides with a score >15 (p <
0.05) were considered significant. Identification of
differentially represented peptides was achieved with
a laboratory-created program to compare MS scan
profile analysis with autoMS(n) scan peptide data-
base searching results. Peptide peaks that matched
with peptide identification results of the same reten-
tion time and m/z were considered successfully
identified.
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Analysis and IPI_human protein database) for spectra
analyses for improved detection of candidate MS peaks.
To confirm that the sequence of each peptide fragment
reported in this study was not present in more than one
protein, all sequences were proven in the blastp database
(http://www.ncbi.nlm.nih.gov/blast/).Quantitative peptide scanning by MRM
MRM was performed with a combination of Shimadzu
HPLC and Applied Bio-systems API3200 mass spec-
trometry. Quantitative scanning was based on parame-
ters from the peptide ELNNALQNLARTI (ESAT-6),
which represents amino acids 64-76 of early secreted
antigenic target protein 6 from mycobacterium tubercu-
losis, which is absent in our samples. 45 ml volume of
extracted serum peptide sample was chromatographed
on an Acclaim PepMap C-18 column with a total flow
of 0.06 ml/min. The precursor ion was isolated with a
mass window of 2.0 m/z units and fragmented (collision
energy = 35%, activation time = 30 ms at Q = 0.25); the
resulting fragment ion was scanned in profile mode
with a mass window of 2.0 m/z unit. According to
API3200 detection sensitivity, we chose target peptides
with m/z values <800 and product ions with relatively
small m/z values for MRM analysis. At least 2 transi-
tions and the product ions were monitored for target
and reference peptides. Signature ion pairs for each
target peptide were selected based on their uniqueness
and chemical stability. Analyst software was used to
extract and integrate transition ion peak areas for each
target peptide.Study focus on peptide m/z 520.3
Verification of the identity of the m/z 520.3 by Q TOF
To verify the peptide m/z 520.3, we synthesized the pep-
tide LLSKLSVLLLEKMG +Oxidation (M) by Shanghai
Qiangyao Biotech Co.,Ltd., Shanghai, China. The synthe-
sized peptide and serum peptide extractions from clin-
ical samples were analyzed with mass spectrometry
Quadrupole orthogonal TOF (Q TOF) (QSTARXL,
Applied Biosystems, USA), with high resolution and
mass accuracy. Samples were directly injected into MS
through a nano spray needle. The instrument was oper-
ated in the positive ion mode. The initial MS scan
utilized an m/z range of 400–2,000, with three precur-
sors selected for interrogation from each MS survey
scan. Precursor selection was based on ion intensity
(peptide signal intensity above ten counts), charge state,
and based on whether the precursor was previously
selected for interrogation (dynamic exclusion). External
calibration was carried out prior to analysis using horse
myoglobin digest peptides.Verification of the expression of peptide m/z 520.3
The synthesized peptide LLSKLSVLLLEKMG +Oxida-
tion (M) was used to assess the method for quantifying
m/z 520.3. The synthetic peptide from ESAT-6 was used
as internal standard. In order to decrease side effects
from endogenous peptides, 5 ml plasma from a person
containing m/z 520.3 near the low limit of quantification
(LLOQ) was used as blank in the experiments described
in sections Accuracy and precision analysis and Stability
analysis of serum peptide m/z 520.3 by MRM below.
Values for cross-contamination of the blank were sub-
tracted from values for the spiked standard samples.
Accuracy and precision analysis Six ion pairs of m/z
520.3 were analyzed. Six calibration standards with
concentrations of 6.25, 12.5, 25, 50, 100 and 200 ng/μl
were used to proof the MRM methods. Three quality con-
trols (QC) with concentrations of 7.5, 75 and 160 ng/μl,
were analyzed to proof accuracy and precision. Each QC
was prepared in parallel experiments.
Stability analysis of serum peptide m/z 520.3 by
MRM Stability studies were conducted using mixed stan-
dards with a synthesized peptide of 1 ng/μl and an internal
standard (IS) of 0.4 ng/μl. Stability of analytes at 4°C was
assessed at intervals of 8, 16 and 24 h in triplicate aliquots.
To proof long-term stability during storage, samples
frozen for up to 2 months were tested at intervals of 20,
40 and 60 days. Sera from 6 healthy controls or their sera
spiked with 50 ng/μl of synthetic peptide were used.
Internal standard was added prior to sample preparation
at each scheduled time, and the stability for each sample
was determined through 6 ion pairs.
Quantification of peptide m/z 520.3 and others in
serum samples
For quantification of m/z 520.3 and other peptides, 11 ion
pairs and then 6 ion pairs of m/z 520.3 were scanned.
Summed peak areas of product ion pairs were calculated.
We also calculated the summed peak areas ratio (SPAR)
of ion pairs generated from target and internal standard
peptide (ESAT-6). SPAR values of groups were compared
with Kruskal-Wallis non-parametric tests.
Establishment of diagnostic models
Ion pairs of the marker peptide were used to establish a diag-
nostic model. SPAR values were used as diagnostic values. As-
partate aminotransferase-to-platelet ratio index (APRI), FIB-4
and Forn’s index were calculated according to the following
formulas: [23-25] APRI = [AST (/ULN)/PLT (109/L)] × 100,
FIB− 4= [age (yr) ×AST (U/L)]/{[PLT (109/L)] × (ALT (U/L)]
1/2}, Forn ’ s index = 7.811 − 3.131 × ln [PLT (109/L)] +
0.781 × ln [GGT (U/L)] + 3.467 × ln [age (yr)] − 0.014 ×
Table 1 Differential peptide identified in LC-MS/MS analysis
PA PA Mean SPI
(E + 05)
p value Fold Differential peptide sequence IP GENE Protein Information
Time(s) m/z MF SF MF/SF Tax Id = 9606
1 2670 545.5 62.52 15.70 0.034 -3.22 AAGFLLMYST + Oxidation (M) IPI00644710 SLC35D2 Isoform2 of UDP-N-acetylglucosamine
2 2910 427.5 16.12 4.55 0.045 2.76 PTNFAPVINHVA IPI00334276 CPNE8 cDNA FLJ25727 fis,clone TST05479
3 3150 520.3 3.26 6.83 0.049 2.14 LLSKLSVLLLEKMG +Oxidation (M) IPI00551024 DAK ATP-dependent dihydroxyacetone kinase
4 2790 414.5 4.97 2.31 0.003 1.68 GPMNMNMGMNM+ Oxidation (M) IPI00030652 ZIC2 Zinc finger protein ZIC 2
5 3390 640.5 22.93 7.92 0.025 2.26 AANSQPQPPRES IPI00221255 MYLK Isoform 2 of Myosin light chain kinase
6 3450 550.5 14.43 4.19 0.023 2.68 AAINKMCVFS + Oxidation (M) IPI00922072 - cDNA FLJ52618
7 4230 816.5 19.91 9.41 0.048 1.83 STPPITSSITPTDTMTSMRTTTS +2 Oxidation (M) IPI00386766 MUC3A Isoform 2 of Mucin-3A
8 2130 327.5 1.73 5.55 0.048 -4.11 MEGNKTWI IPI00455038 OR2A14 Olfactory receptor 2A14
9 2070 787.5 6.29 3.16 0.046 1.55 ELGLEMTAGFGLGGLRLTALQAQ + Oxidation (M) IPI00063762 HPDL 4 Hydroxyphenylpyruvate dioxygenase-like protein
10 2910 1013.5 4.04 7.45 0.044 -2.63 NYEESIKMPINEPAPGKKKSQIQEYV + Oxidation (M) IPI00218297 HPD 4 Hydroxyphenylpyruvate dioxygenase
11 3030 869.5 40.06 20.43 0.049 1.53 LPCTESSSSMPGLGMVPPPPPPLPGM + 2 Oxidation (M) IPI00742944 FMN2 FMN2 195 kDa protein
12 3390 881.5 10.90 4.28 0.031 1.99 MTCTYVCVCVYMYVCIYIYMY + Oxidation (M) IPI00943356 - Putative uncharacterized protein (Fragment)
13 3810 766.5 6.08 2.44 0.020 1.75 GTRRRCPCAPRSGLPGRRSVD IPI00936509 - LOC100287493; hypothetical protein
14 4230 839.5 10.26 4.01 0.035 2.21 EEPPPPSS IPI00386642 MEF2B LOC729991 Isoform 1 of UPF0402 protein
15 2070 682.5 24.48 51.19 0.048 -2.68 DQGLYHCIATEN IPI00019209 - SEMA3C cDNA FLJ55486
16 3270 1129.5 7.23 5.98 0.021 -5.32 CLSYMALLRLPKKRGTFIEFRNGMLNISP + Oxidation (M) IPI00294903 PMM1 Phosphomannomutase 1
17 3030 981.5 5.35 8.00 0.024 -1.92 NVARMLALALAESAQQAST + Oxidation (M) IPI00787743 ARHGAP32 Isoform 1 of Rho/Cdc42/Rac GTPase-activating protein
18 2790 757.5 71.50 30.99 0.049 1.8 DEPVSGELVSVAHALSLPAESY IPI00107104 CXorf26 UPF0368 protein Cxorf26
19 3150 1142.5 5.49 2.23 0.045 1.91 LTVLWYGVVHTSALVRCTAARMFELTLRGM + 2 Oxidation (M) IPI00101291 KIAA1468 KIAA1468, isoform CRA
20 3450 901.5 14.39 7.12 0.008 1.58 MPKTWISWAEIRSHTSSLSMSHP +2 Oxidation (M) IPI00643635 C20orf57 DUSP15 Dual specificity phosphatase 15
21 3930 857.5 15.45 5.17 0.036 2.33 AVNWVARSLYWTHTGTEHIEVT IPI00018681 LRP5L Isoform 2 of Low-density lipoprotein receptor-related
protein 5-like protein
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diagnostic sensitivity and specificity.
ELISA
Serum DAK protein was examined by an ELISA Kit
(Assay Biotechnology Company, Inc. California, USA).
The DAK antibody detects endogenous levels of total
DAK protein. All 126 serum samples from enrolled CHB
patients were analyzed.
Statistical analysis
The χ2 test was used for testing categorical variables; the
Student’s t-test was used for continuous variables;
univariate analysis with SPSS 19.0 (SPSS Inc, Chicago)
was used. ROC curve analysis was applied to determine
the cutoff value for peptide levels by the 0.1-criterion,
and the areas under curves (AUCs) were calculated.
P < 0.05 was considered statistically significant.
Results
Discovery study
In the discovery study, LC-MS/MS was performed with
serum samples from 40 CHB patients classified accor-
ding to the degree of fibrosis and inflammation into
Early Disease (ED, including 10 patients with S0G0 andFigure 1 SPAR values of 6 ion pairs from peptide m/z 520.3. Box plot
in 86 serum samples from CHB patients. A: Patients were classified in 5 gro
n = 16, S4: n = 15). SPAR values of 6 ions of m/z 520.3 display a statistically
colors represent different ions (blue = 520.3/176.1, green = 520.3/353.7, brow
520.3/593.1). B: SPAR values decrease along with liver inflammation severity
have no statistically significant difference between groups classified by HBe
difference among groups classified by HBV-DNA levels (HBV-DNA: 104 ~ 10510 patients with S1G1) or Advanced Disease (AD, 10
patients with S3G3 and 10 patients with S4G4). Their
characteristics are shown in Additional file 1: Table S1.
In total, 296 differential peptide peaks were evaluated by
LC-MS/MS and ProfileAnalysis software. 21 independ-
ent peaks with significantly different mean SPI values
between two groups were identified (Table 1). We pro-
vide the typical MS maps in m/z range of 500-800 of dif-
ferent stages (S0, G0, S1, G1, S3, G3, S4, G4, Additional
file 2: Figure S1).
Validation study
Peptide m/z 520.3 was singled out by MRM analysis
In the validation study, MRM was conducted with serum
samples from 86 CHB patients. All patients could be
sorted out to 4 classifications regarding fibrotic degree
(S0-S4), inflammatory grade (G0-G4), HBeAg carrier
(HBeAg + or HBeAg-), and HBV-DNA level. Clinical
characteristics are shown in Additional file 1: Table S1.
Selection of target peptides was based on the 21 peptides
found differentially represented in the discovery study.
11 of those were selected as target peptides (m/z <800).
These generated 2 ~ 4 ion pairs each, resulting in a total
of 38 product ion pairs that were exploited and con-
firmed as stable and reliable. Selected transitions werefigure shows values of 4-6 ion pairs generated from peptide m/z 520.3
ups according to fibrosis stages (S0: n = 13, S1: n = 22, S2: n = 20, S3:
significant decrease in groups S1 ~ S4 as compared to S0. Different
n = 520.3/459.8, purple = 520.3/503.3, yellow = 520.3/351.3, red =
in the 5 groups classified by inflammation grades. C: SPAR values
Ag carrier status. D: SPAR values have no statistically significant
; 105 ~ 106; 106 ~ 107; ≥107).
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maximize the number of data points across the peaks, in
the final assay one single transition was chosen from
each target peptide (Additional file 3: Table S2: ion pairs
marked in red colour were analyzed). For the above-
selected 11 ion pairs, SPAR values were calculated and
statistically analyzed among subgroups (S0-S4 and G0-
G4). Only SPAR values of 520.3/176.1 were significantly
different among S1-S4 as compared to S0 and G1-G4 as
compared to G0 (p < 0.05; Figure 1A/B), whereas those of
the 10 other ions were not (we show data of additional 2
ions in Additional file 4: Figure S2). Thus, we focused on
finding out whether serum peptide m/z 520.3 levels cor-
relates with disease progression in CHB patients.
Accuracy, precision and stability of peptide m/z 520.3 in
MRM methodology
The correlation coefficients (r) of calibration curves
were >0.99 for 735.5/389.3 for ESAT-6 and six ions of
m/z 520.3, as determined by linear analysis. They had
an accuracy of 100 ± 20% in the quantification range
(Additional file 5: Figure S3).
Intra-day accuracy and precision varied from 92.1% to
113.8% and from 2.1% to 11.0%, respectively. Inter-dayFigure 2 Mass spectrometry and tandem mass spectrometry of pepti
500 to 800 including target peptide peak with m/z of 520.3 (520.6272). B: T
including peptide with m/z of 520.3 (520.9580). Four transition spectra with
are also marked in the figure.accuracy and precision varied from 95.3% to 107.4% and
from 6.1% to 10.9%, respectively (Additional file 6: Table
S3). These values are well within acceptance criteria, as
recommended by the China FDA guidelines (2005, China
Pharmacopoeia).
Relative errors (RE%) for 6 ions of m/z 520.3 were
2.6 ~ 15.3% at intervals of 8 ~ 24 h and at 4°C. Ra-
tios of standard and average values (STD/AVE) were
0.120 ~ 0.199 at intervals of 20 ~ 60 days at -80°C,
indicating acceptable sample storage short or long
term stability (Additional file 7: Table S4).
Quantification and identification of peptide m/z 520.3
Peptide m/z 520.3 displayed 4 fragment ions with double
charges (520.3/176.1; 520.3/353.7; 520.3/459.8; 520.3/
503.3) and 2 with single charges (520.3/351.3; 520.3/593.1)
(Figure 2).
We identified the peptide sequence with m/z of
520.3 as LLSKLSVLLLEKMG+Oxidation (M) by Mascot
IPI_human database searching. Its accession number in
the IPI database is IP100551024, and the gene symbol is
dihydroxyacetone kinase (DAK). In order to verify
the peptide m/z 520.3, we synthesized the peptide
LLSKLSVLLLEKMG+Oxidation (M). MS and MS/MSde with m/z 520.3. A: Mass spectrometry (MS) in m/z range from
andem mass spectrometry (MS/MS) in m/z range from 0 to 1100
double charge (520.3/176.1; 520.3/353.7; 520.3/459.8; 520.3/503.3)
Figure 3 Spectrogram of synthesized DAK peptide and peptide extracted from patient serum through Qstar mass spectrometry.
A to C represent MS profiles of synthetic peptide. D to F represent MS profiles of serum extracted peptide from a patient with fibrosis stage S2
(Sample No. 62). A and D show the ms profile. B and E are a partial enlargement of 520.3 (also 520.6). C and F are MS-MS of 520.3 (also 520.6),
partial magnification and MS-MS of 50 ng/μl synthetic DAK peptide.
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extracted from a clinical sample with fibrosis stage S2G1
(Sample No. 64) were generated by high resolution mass
spectrometry Q TOF. The exact m/z of the LLSKLSVL
LLEKMG+Oxidation (M) peptide was 520.6 (Figure 3A
and D), and similar MS/MS profiles (Figure 3C and F) of
the precursor ion 520.6 were obtained with the synthe-
sized peptide and the peptide extracted from patient
serum. As can be seen from partial enlargement, the
characters of +3 ions were obvious (Figure 3B and E).
MS-MS values were identical with calculated ones (data
not shown), and specific precursor and fragment ions
were clearly detectable (Additional file 5: Figure S3).
Furthermore, MS-MS profiles for 520.6 and 520.3 were
very similar (data not shown). These results confirm pep-
tide identification data, suggesting that the differentially
represented peptide 520.3 detected in HCT and API3200
mass spectrometry is definitely LLSKLSVLLLEKMG+
Oxidation (M).
In order to confirm the presence of 520.3, we detected
6 ion pairs in each of 86 samples. SPAR values statis-
tically decreased among groups from mild to severe
fibrotic stages. Ion representation levels were statistically
different in groups S1-S4, as compared to S0 (Figure 1A).
SPAR values of 6 ion pairs as well gradually decreased
mild to severe inflammatory grades G0 to G4 (Figure 1B).
No statistically significant difference was found among
groups classified by HBeAg carrier status or HBV-DNA
levels (Figure 1C/D). Our results suggest that serum
peptide m/z 520.3 levels reflect disease progression sinceTable 2 Diagnostic values of established ions of peptide m/z
S2-S4 versus S0-S1
AUROC 95% CI Cut-off value Sensitivity Specif
520.3/176.1 0.915 0.855 0.976 1.401 0.886 0.902
520.3/353.7 0.892 0.818 0.967 0.161 0.829 0.922
520.3/459.8 0.724 0.617 0.832 0.368 0.629 0.725
520.3/503.3 0.891 0.824 0.957 12.751 0.851 0.865
520.3/351.3 0.871 0.793 0.949 43.85 0.882 0.852
520.3/593.1 0.908 0.842 0.974 1.769 0.829 0.903
FIB-4 0.793 0.7 0.885 222.70 0.757 0.801
Forn’s Index 0.811 0.715 0.906 -317.1 0.857 0.686
APRI 0.685 0.573 0.798 33.79 0.771 0.643
G2-G4 versus G0-G1
AUROC 95% CI Cut-off value Sensitivity Specif
520.3/176.1 0.84 0.756 0.924 1.301 0.788 0.811
520.3/353.7 0.843 0.763 0.923 0.184 0.870 0.666
520.3/459.8 0.694 0.581 0.807 0.335 0.788 0.509
520.3/503.3 0.856 0.779 0.933 10.375 0.910 0.679
520.3/351.3 0.902 0.839 0.964 43.60 0.911 0.851
520.3/593.1 0.868 0.792 0.945 1.653 0.876 0.831its detection levels consistently rise with the degree of
liver fibrosis and inflammation.
Diagnosis study
We established 6 models with ions of peptide m/z 520.3
(176.1, 353.7, 459.8, 503.3, 351.3, 593.1). Diagnostic
values were the respective SPAR values. Values of
AUROC, 95% CI, cut-off value, sensitivity and specificity
are shown in Table 2. AUROCs of 6 ions models (176.1,
353.7, 459.8, 503.3, 351.3, 593.1) distinguishing fibrosis
stages S2-S4 from S0-S1 were 0.915, 0.892, 0.724, 0.891,
0.871 and 0.908, respectively (Figure 4B-1). AUROCs
distinguishing S3-S4 from S0-S2 were 0.924, 0.825,
0.797, 0.920, 0.849 and 0.804, respectively (Figure 4B-2).
AUROCs of APRI, FIB-4 and Forn’s index were 0.793,
0.811 and 0.685 to distinguish S2-S4 from S0-S1, and
0.801, 0.739 and 0.697 to distinguish S3-S4 from S0-S2
(Figure 4A). Ion models of m/z 520.3, with one excep-
tion (520.3/459.8), had a better diagnostic power to
identify liver fibrosis stages, as compared to the above
clinical serological models (APRI, FIB-4 and Forn’s index).
In AUROC comparisons between ions of peptide m/z
520.3, APRI, FIB-4 and Forn’s index, t-test and P-value are
provided in Table 3 to indicate statistical differences. Most
sensitivities and 1-specificities of peptide ions 520.3/353.7,
520.3/459.8 and 520.3/503.3 were significantly superior to
APRI, FIB-4 and Forn’s index.
AUROCs of 6 ions models (176.1, 353.7, 459.8, 503.3,
351.3, 593.1) discriminating inflammatory grades G2-G4
from G0-G1 were 0.840, 0.843, 0.694, 0.856, 0.902 and520.3 models and others
S3-S4 versus S0-S2
icity AUROC 95% CI Cut-off value Sensitivity Specificity
0.924 0.936 0.948 1.287 0.868 0.98
0.825 0.855 0.929 0.129 0.732 0.919
0.797 0.692 0.902 0.337 0.692 0.902
0.92 0.916 0.965 9.050 0.862 0.979
0.849 0.954 1.000 28.91 0.745 0.954
0.804 0.795 0.947 1.487 0.71 0.899
0.801 0.705 0.896 408.77 0.836 0.645
0.739 0.635 0.843 -416.01 0.673 0.742
0.697 0.577 0.816 59.94 0.655 0.677
G3-G4 versus G0-G2
icity AUROC 95% CI Cut-off value Sensitivity Specificity
0.756 0.818 0.953 1.186 0.705 0.760
0.763 0.69 0.889 0.179 0.806 0.720
0.581 0.61 0.852 0.235 0.621 0.680
0.779 0.819 0.956 10.375 0.887 0.910
0.839 0.813 0.96 41.82 0.901 0.842
0.792 0.66 0.914 1.644 0.874 0.792
Figure 4 AUROCs of ion pairs generated from peptide m/z 520.3. Six models established by ions of peptide m/z 520.3 (176.1, 353.7, 459.8,
503.3, 351.3 and 593.1) and three serological models currently in clinical use (APRI, FIB-4, Forn’s Index) were evaluated for their diagnostic
potential by AUROC. A-1: AUROCs of APRI, FIB-4, Forn’s Indices are 0.724 ~ 0.876 (S2-4 versus S0-1). A-2: AUROCs of APRI, FIB-4, Forn’s Indices are
0.758 ~ 0.839 (S3-4 versus S0-2). B-1: AUROCs of 6 ions from 520.3 models are 0.724 ~ 0.940 (S2-4 versus S0-1). B-2: AUROCs of 6 ions from 520.3
models are 0.883 ~ 0.937 (S3-4 versus S0-2). C-1: AUROCs of 4 ions from 520.3 models are 0.694 ~ 0.856 (G2-4 versus G0-1). C-2: AUROCs of 4 ions
from 520.3 models are 0.731 ~ 0.888 (G3-4 versus G0-2).
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shing G3-G4 from G0-G2 were 0.886, 0.790, 0.731,
0.888, 0.887 and 0.787, respectively (Figure 4C-2). The
results indicate that ion models based on 520.3 also had
good sensitivity and specificity in discriminating liver
inflammation grades of CHB patients.
Detection of serum DAK protein in CHB patients
From all 126 patients, serum DAK protein was examined
by ELISA. DAK levels mildly decreased with liver fibro-
sis and inflammation worsening (Figure 5A-1/B-1).
When comparing fibrosis or inflammation subgroups,
most of them had no statistically significant difference
(Additional file 8: Table S5). The AUROC of DAK was
0.678 to distinguish S2-S4 from S0-S1 and 0.652 to dis-
tinguish S3-S4 from S0-S2 (Figure 5A-2/A-3). Further,
AUROC of DAK was 0.736 to distinguish G2-G4 from
G0-G1 and 0.720 to distinguish G3-G4 from G0-G2
(Figure 5B-2/B-3).
Discussion
Native peptides are regarded as surrogate markers for
protease activity in biological samples. Clinical peptido-
mics has been increasingly and widely used over the past
few years, especially as potential biomarkers in cancerdiagnosis [22]. Serum peptide quantitation represents
challenge and technical difficulty to test and verify clin-
ical significance. Due to recent technological advances,
MRM has become a powerful method for defining
the amount of a specific peptide sequence. It provides
highly selective and sensitive quantification of candidate
peptide fragments, whereby multiple assays can be
performed in a single run. However, using these novel
methods in liver disease has not yet been reported. In
our study, we used LC-MS/MS-based peptidomics com-
bined with MRM to identify serum peptides potentially
useful as markers for liver fibrosis or inflammation
progression in CHB patients. We robustly found serum
ions levels of peptide m/z 520.3 decreased with more
advanced fibrosis and inflammation, as compared to
mild ones. Five from six diagnostic ions models of 520.3
(176.1, 353.7, 503.3, 351.3 and 593.1) were relatively
accurate in discriminating degrees of liver fibrosis and
inflammation, with one excepton, that is the ions 459.8
model. The new diagnostic models showed consistently
high sensitivity and specificity, and markedly improved
the discriminatory power to diagnose fibrosis and in-
flammation degrees S2/G2. Therefore, we suggest usage
of serum ion model from peptide m/z 520.3 to guide
timing of antiviral treatment and avoid liver biopsy.
Table 3 AUROCs comparison between ions of peptide m/z 520.3, APRI, FIB-4 and Forn’s index
1-Specificity S0-2 vs S3-4 Sensitivity S0-2 vs S3-4
Mean Std. deviation Std. error mean 95% CI of
the difference
t df P-value Mean Std. deviation Std. error mean 95% CI of
the difference
t df P-value
APRI 520.3/176.1 (0.01) 0.48 0.05 (0.12) 0.10 (0.16) 76.00 0.87 0.09 0.60 0.07 (0.04) 0.23 1.34 76.00 0.19
520.3/353.7 0.18 0.46 0.06 0.06 0.29 3.07 63.00 0.00 0.18 0.56 0.07 0.04 0.32 2.62 63.00 0.01
520.3/459.8 0.16 0.41 0.05 0.06 0.27 3.18 62.00 0.00 0.15 0.57 0.07 0.01 0.30 2.15 62.00 0.04
520.3/503.3 0.08 0.43 0.05 (0.03) 0.19 1.54 60.00 0.13 0.18 0.57 0.07 0.04 0.33 2.53 60.00 0.01
520.9/351.3 (0.03) 0.51 0.05 (0.14) 0.08 (0.56) 86.00 0.57 0.02 0.64 0.07 (0.12) 0.15 0.25 86.00 0.80
520.9/593.1 0.07 0.48 0.06 (0.04) 0.18 1.30 76.00 0.20 0.06 0.59 0.07 (0.08) 0.19 0.86 76.00 0.39
FIB-4 520.3/176.1 (0.05) 0.52 0.06 (0.17) 0.07 (0.84) 76.00 0.40 0.11 0.58 0.07 (0.02) 0.25 1.74 76.00 0.09
520.3/353.7 0.15 0.49 0.06 0.03 0.27 2.42 63.00 0.02 0.20 0.54 0.07 0.06 0.33 2.95 63.00 0.00
520.3/459.8 0.14 0.44 0.06 0.03 0.25 2.49 62.00 0.02 0.17 0.55 0.07 0.03 0.31 2.44 62.00 0.02
520.3/503.3 0.06 0.45 0.06 (0.05) 0.18 1.08 60.00 0.29 0.20 0.55 0.07 0.05 0.34 2.77 60.00 0.01
520.9/351.3 (0.07) 0.53 0.06 (0.18) 0.04 (1.22) 86.00 0.23 0.04 0.62 0.07 (0.09) 0.17 0.59 86.00 0.56
520.9/593.1 0.03 0.53 0.06 (0.09) 0.15 0.51 76.00 0.61 0.08 0.57 0.07 (0.05) 0.21 1.24 76.00 0.22
Forn’s 520.3/176.1 (0.08) 0.49 0.06 (0.19) 0.03 (1.42) 76.00 0.16 0.13 0.60 0.07 (0.00) 0.27 1.93 76.00 0.06
520.3/353.7 0.11 0.47 0.06 (0.01) 0.22 1.83 63.00 0.04 0.22 0.55 0.07 0.08 0.36 3.21 63.00 0.00
520.3/459.8 0.10 0.42 0.05 (0.01) 0.20 1.82 62.00 0.04 0.19 0.56 0.07 0.05 0.33 2.72 62.00 0.01
520.3/503.3 0.02 0.43 0.06 (0.09) 0.13 0.32 60.00 0.75 0.22 0.57 0.07 0.08 0.37 3.06 60.00 0.00
520.9/351.3 (0.10) 0.51 0.05 (0.20) 0.01 (1.77) 86.00 0.08 0.05 0.64 0.07 (0.08) 0.19 0.79 86.00 0.43
520.9/593.1 0.00 0.50 0.06 (0.11) 0.11 0.03 76.00 0.98 0.10 0.59 0.07 (0.04) 0.23 1.45 76.00 0.15
1-Specificity S0-1 vs S2-4 Sensitivity S0-1 vs S2-4
Mean Std. deviation Std. error mean 95% CI of
the difference
t df P-value Mean Std. deviation Std. error mean 95% CI of
the difference
t df P-value
APRI 520.3/176.1 0.02 0.55 0.06 (0.11) 0.14 0.24 76.00 0.81 0.11 0.56 0.06 (0.01) 0.24 1.79 76.00 0.08
520.3/353.7 0.16 0.52 0.06 0.03 0.29 2.50 63.00 0.02 0.21 0.53 0.07 0.07 0.34 3.12 63.00 0.00
520.3/459.8 0.20 0.48 0.06 0.08 0.32 3.31 62.00 0.00 0.10 0.56 0.07 (0.04) 0.24 1.40 62.00 0.17
520.3/503.3 0.12 0.47 0.06 0.00 0.25 2.05 60.00 0.04 0.18 0.58 0.07 0.03 0.33 2.47 60.00 0.02
520.9/351.3 (0.03) 0.58 0.06 (0.15) 0.09 (0.51) 86.00 0.61 0.05 0.61 0.07 (0.08) 0.18 0.70 86.00 0.49
520.9/593.1 0.03 0.55 0.06 (0.10) 0.15 0.42 76.00 0.68 0.12 0.56 0.06 (0.01) 0.24 1.82 76.00 0.07
FIB-4 520.3/176.1 0.02 0.56 0.06 (0.10) 0.15 0.36 76.00 0.72 0.10 0.54 0.06 (0.02) 0.23 1.66 76.00 0.10
520.3/353.7 0.18 0.51 0.06 0.05 0.31 2.75 63.00 0.01 0.18 0.52 0.07 0.05 0.31 2.80 63.00 0.01
520.3/459.8 0.22 0.48 0.06 0.10 0.34 3.59 62.00 0.00 0.07 0.56 0.07 (0.07) 0.21 1.05 62.00 0.30
520.3/503.3 0.14 0.47 0.06 0.02 0.26 2.40 60.00 0.02 0.16 0.58 0.07 0.01 0.30 2.08 60.00 0.04
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Table 3 AUROCs comparison between ions of peptide m/z 520.3, APRI, FIB-4 and Forn’s index (Continued)
520.9/351.3 (0.02) 0.59 0.06 (0.15) 0.10 (0.38) 86.00 0.70 0.04 0.59 0.06 (0.09) 0.16 0.55 86.00 0.58
520.9/593.1 0.03 0.57 0.06 (0.09) 0.16 0.53 76.00 0.60 0.10 0.54 0.06 (0.02) 0.23 1.69 76.00 0.10
Forn’s 520.3/176.1 (0.03) 0.56 0.06 (0.16) 0.09 (0.53) 76.00 0.60 0.19 0.56 0.06 0.06 0.31 2.93 76.00 0.00
520.3/353.7 0.11 0.53 0.07 (0.02) 0.24 1.67 63.00 0.10 0.28 0.51 0.06 0.15 0.41 4.40 63.00 0.00
520.3/459.8 0.15 0.49 0.06 0.02 0.27 2.40 62.00 0.02 0.17 0.54 0.07 0.04 0.31 2.53 62.00 0.01
520.3/503.3 0.07 0.48 0.06 (0.05) 0.20 1.21 60.00 0.23 0.25 0.56 0.07 0.11 0.40 3.55 60.00 0.00
520.9/351.3 (0.07) 0.57 0.06 (0.20) 0.05 (1.22) 86.00 0.23 0.11 0.62 0.07 (0.02) 0.24 1.64 86.00 0.11
520.9/593.1 (0.02) 0.56 0.06 (0.15) 0.10 (0.35) 76.00 0.72 0.19 0.56 0.06 0.06 0.31 2.96 76.00 0.00
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http://www.translational-medicine.com/content/11/1/234The biomarker peptide m/z 520.3 was identified as
peptide fragment from DAK, a bi-functional ATP-
dependent dihydroxyacetone kinase. Human liver DAK
characteristics and function were identified in 2005 [26].
DAK is a key enzyme that specifically inhibits MDA5-
mediated innate antiviral signaling [27]. It is also associ-
ated with therapy outcome and responder classification
with an accuracy of 85.7% for chronic hepatitis C
patients [28]. So far, the molecular mechanisms by which
a peptide fragment of DAK can reflect the degree of liver
fibrosis and inflammation are unknown. The peptide
maybe a marker of immune dysregulation associated
with more pronounced hepatic inflammation and ad-
vanced liver disease.
We designed a serum peptidomic protocol suggesting
a DAK peptide fragment as indicator of advanced fibro-
sis and inflammation in CHB patients, however, it is
difficult to detect DAK peptide levels with routine clinicalFigure 5 Detection of serum DAK protein in CHB patients. A-1: Serum
fibrosis degrees (S0-S4 subgroups) in 126 CHB patients. A-2: AUROC of DAK
0.652 (S3-4 versus S0-2). B-1: Serum DAK levels decrease with disease sever
subgroups) in 126 CHB patients. B-2: AUROC of DAK protein is 0.736 (G2-4laboratory methods. Upon testing and verifying DAK pro-
tein expression in sera, results were consistent with serum
peptidomics, however without statistical difference in
CHB patients. It is possible that only a spliced form, which
contains LLSKLSVLLLEKMG, but not full length DAK
protein is an indicator for advanced fibrosis and inflam-
mation. The potential mechanism behind needs further
investigation. It may also be possible that MS based MRM
is required for a clinical application as described for the
DAK peptide. Difficulties then include depency on such
MS instrument that is not available in most general hos-
pital. The next step should be the development of a
peptide-ELISA protocol to detect the DAK fragment
LLSKLSVLLLEKMG in the serum [29,30].
Nonetheless, peptide m/z 520.3 of DAK as detected by
serum peptidomics provides a novel non-invasive biomarker
for evaluating degrees of liver fibrosis and inflammation in
CHB patients that can be further developed.DAK levels decrease with disease severity among groups classified by
protein is 0.678 (S2-4 versus S0-1). A-3: AUROC of DAK protein is
ity among groups classified by inflammatory grades (G0-G4
versus G0-1). B-3: AUROC of DAK protein is 0.720 (G3-4 versus G0-2).
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Additional file 1: Table S1. Clinical characteristics of enrolled patients
in LC-MS/MS and MRM study groups.
Additional file 2: Figure S1. Representative MS spectra of serum
sample. Representative MS spectra of serum sample of stages (S0, S1, S3,
S4, G0, G1, G3, G4) with retention time 52.5 ± 0.2 min and m/z range of
500-800. The corresponding amplified spectra with m/z rang 510-530
were shown on the right in which the DAK peptide (m/z 520.3) were
labeled by arrow.
Additional file 3: Table S2. Selected MRM transitions for the eleven
analyzed differential peptides.
Additional file 4: Figure S2. SPAR values and AUROCs of ions from
peptides m/z 414.9 and m/z 735.5. The figure shows SPARs and AUROCs
of 2 ions from m/z 414.9 (132.6, 226.6) and 4 ions from m/z 735.5 (215.3,
389.3, 460.3, 524.3) in 86 serum samples from CHB patients. Patients were
classified into 5 groups according to fibrosis stages (S0: n = 13, S1: n = 22,
S2: n = 20, S3: n = 16, S4: n = 15). A-1 and B-1: SPAR values of ions from
m/z 414.9 and 735.5 display no statistically significant difference in
groups (S1-S4 versus S0). A-2/3 and B-2/3: AUROCs of ions from m/z
414.9 are less than 0.5 and ions of m/z 735.5 are less than 0.8 (S2-S4
versus S0-1 or S3-4 versus S0-2).
Additional file 5: Figure S3. Calibration curves for 735.5/389.3 of ESAT-
6 and 6 analytes of peptide m/z 530.3. Seven calibration standards with
concentrations of 6.25, 12.5, 25, 50, 100 and 200 ng/μl were used for
MRM analysis. A: The correlation coefficients (r) of the calibration curves
were >0.99 for 735.5/389.3 of ESAT-6, as determined by linear analysis. B:
6 ion pairs were analyzed including 4 son ions with double charge and 2
with single charge from 520.3. The correlation coefficients (r) of the
calibration curves were >0.99 for all six analytes, as determined by linear
analysis. All 6 ion pairs in the quantification range have an accuracy of
100 ± 20%.
Additional file 6: Table S3. Precision and accuracy experiments of
520.3 ions.
Additional file 7: Table S4. A. Stability of analyst 4°C for 24 h. B. Stability
of analyst -80°C for 2 months.
Additional file 8: Table S5. ELISA results comparison among fibrosis or
inflammation subgroups.
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